Summary

Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department

Alquézar A, Santaló M, Rizzi M, Gich I, Grau M, Sionis A, Ordóñez-Llanos J


Affiliation of the authors

Servicio de Urgencias, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain. Servicio de Epidemiología Clínica, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain. Servicio de Cardiología, Institut d’Investigacions Biomédiques- Sant Pau, Barcelona, Spain. Servicio de Bioquímica Clínica, Institut d’Investigacions Biomédiques-Sant Pau Barcelona, Spain. Departamento de Bioquímica y Biología Molecular, Universidad Autónoma, Barcelona, Spain.

DOI

Quote

Alquézar A, Santaló M, Rizzi M, Gich I, Grau M, Sionis A, et al. Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department. Emergencias. 2017;29:237-44

Summary

Objectives.

To assess the diagnostic yield of a high-sensitivity copeptin (hs-copep) assay alone or in combination with a high-sensitivity cardiac troponin T (hs-cTnt) assay for the diagnosis of non-ST segment elevation acute coronary syndrome (NSTEMI) in patients with chest pain in the emergency department (ED). The secondary aim was to assess

the 1-year prognostic utility of these biomarkers in this clinical context.

Material and methods. Retrospective observational study of a series of patients attended for chest pain suggesting myocardial ischemia in 5 Spanish ED. The first blood drawn in the ED was used for hs-copep and hs-cTnt assays, which were processed in a single laboratory serving all centers. Diagnostic utility was assessed by sensitivity, specificity, positive and negative predictive values and likelihood ratios, and the area under the receiver operating characteristic curve (ROC). We also performed a separate analysis with data for the subgroup of patients with early detection of symptoms (3 h of onset of symptoms). We recorded complications, mortality or reinfarction occurring within a year of the index event.

Results.

We included 297 patients; 63 (21.2%) with NSTEMI. The median age was 69 years (interquartile range, 70–76 years), and 199 (67%) were men. The ROC was 0.89 (95% CI, 0.85–0.94) for the hs-cTnt assay, 0.58 (95% CI, 0.51–0.66) for the hscopep

assay, and 0.90 (95% CI, 0.86–0.94) for the 2 assays combined. The ROC for the 2 assays combined was not significantly better than the ROC for the hs-cTnt by itself (P=.89). We saw the same pattern of results when we analyzed the subgroup of patients who presented early. Sixty percent of the complications occurred in patients with elevated findings on both assays. Elevated hs-copep findings did not provide prognostic information that was not already provided by hs-cTnt findings (P=.56).

Conclusion. The hs-copep assay does not increase the diagnostic or prognostic yield already provided by the hs-cTnt assay in patients suspected of myocardial infarction in the ED.

 

More articles by the authors

Leave a Reply

Your email address will not be published. Required fields are marked *

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.